Current Approaches to Transplantation for FLT3-ITD AML.


PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative therapy and the development of FLT3 TKIs have significantly improved remission rates and overall survival. The value and challenges of MRD assessment in FLT3 disease are discussed and current mechanisms of relapse are explored, as are the ongoing questions in the field that current clinical trials are seeking to answer. FLT3-ITD mutations are common in acute myeloid leukemia and historically have been associated with a poor prognosis, but with the incorporation of FLT3 TKIs and routine use of allogeneic stem cell transplant as consolidative therapy, outcomes have improved dramatically. Ongoing research seeks to answer how and when to best use current therapies, and how to overcome resistance to FLT3 inhibition.


Curr Hematol Malig Rep


Hunter BD,Chen YB




Has Abstract


2020-02-01 00:00:00














  • Role of minimal residual disease evaluation in leukemia therapy.

    abstract::In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: Campana D

    更新日期:2008-07-01 00:00:00

  • Lenalidomide in myelodysplastic syndromes: where do we go from here?

    abstract::Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: Sirulnik LA,Stone RM

    更新日期:2008-01-01 00:00:00

  • Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Chander U,Leeman-Neill RJ,Bhagat G

    更新日期:2018-08-01 00:00:00

  • Cutaneous T-cell lymphoma: Biologic targets for therapy.

    abstract::Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Choi J,Foss F

    更新日期:2007-10-01 00:00:00

  • The Future of Targeting FLT3 Activation in AML.

    abstract::Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Leick MB,Levis MJ

    更新日期:2017-06-01 00:00:00

  • Update on antigen-specific immunotherapy of acute myeloid leukemia.

    abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Buckley SA,Walter RB

    更新日期:2015-06-01 00:00:00

  • Leveraging Hypomethylating Agents for Better MDS Therapy.

    abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Bradley TJ,Watts JM,Swords RT

    更新日期:2018-12-01 00:00:00

  • Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

    abstract:PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

    更新日期:2019-10-01 00:00:00

  • Role of autologous stem cell transplantation in multiple myeloma.

    abstract::High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Kumar S

    更新日期:2007-05-01 00:00:00

  • Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

    abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

    journal_title:Current hematologic malignancy reports

    pub_type: 已发布勘误


    authors: Zappasodi R,Wolchok JD,Merghoub T

    更新日期:2019-02-01 00:00:00

  • An immune dysregulation in MPN.

    abstract::Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Barosi G

    更新日期:2014-12-01 00:00:00

  • Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

    abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

    更新日期:2012-09-01 00:00:00

  • Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

    abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Dhawan R,Marks DI

    更新日期:2017-04-01 00:00:00

  • Primary mediastinal large B-cell lymphoma.

    abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: Dabrowska-Iwanicka A,Walewski JA

    更新日期:2014-09-01 00:00:00

  • Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

    abstract::Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Betcher J,Dow E,Khera N

    更新日期:2016-08-01 00:00:00

  • Frailty in Hematologic Malignancy.

    abstract:PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Koll TT,Rosko AE

    更新日期:2018-06-01 00:00:00

  • Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

    abstract::The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Hebb J,Kohrt H

    更新日期:2015-12-01 00:00:00

  • Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.

    abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Pemmaraju N,Gupta V,Mesa R,Thompson MA

    更新日期:2015-12-01 00:00:00

  • Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

    abstract::Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Selimoglu-Buet D,Solary E

    更新日期:2014-12-01 00:00:00

  • Twitter Use in the Hematopoietic Cell Transplantation Community.

    abstract:PURPOSE OF REVIEW:Social media has revolutionized the access and exchange of information in healthcare. The microblogging platform Twitter has been used by blood and marrow transplant physicians over the last several years with increasing enthusiasm. We review the adoption of Twitter in the transplant community and its...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Patel SS,Majhail NS

    更新日期:2018-02-01 00:00:00

  • Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

    abstract::Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

    更新日期:2017-06-01 00:00:00

  • Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.

    abstract::The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: La Rosée P,Hochhaus A

    更新日期:2008-04-01 00:00:00

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?

    abstract::Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Lekakis LJ,Cooper BW,de Lima MG

    更新日期:2014-06-01 00:00:00

  • Chemotherapy for patients with acute myeloid leukemia in first remission.

    abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Bradstock K

    更新日期:2006-06-01 00:00:00

  • Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

    abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Kahl BS

    更新日期:2009-10-01 00:00:00

  • The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.

    abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Patel AA,Odenike O

    更新日期:2020-12-01 00:00:00

  • Infant acute lymphoblastic leukemia: Lessons learned and future directions.

    abstract::Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Pieters R

    更新日期:2009-07-01 00:00:00

  • Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.

    abstract::Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Chung CG,Poligone B

    更新日期:2015-12-01 00:00:00

  • Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

    abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Callejas-Díaz A,Gea-Banacloche JC

    更新日期:2014-03-01 00:00:00

  • Blastic Plasmacytoid Dendritic Cell Neoplasm.

    abstract:PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Khoury JD

    更新日期:2018-12-01 00:00:00